Gian Nutal Schädli, Co-founder and CEO of CompagOs, was interviewed by Supertrends about the role of bioprinted bone models in personalized medicine.
He shares how CompagOs generates and uses 3D-printed bone models to provide oncologists with early warning systems for bone metastasis, as well as their potential applications in drug testing and regenerative medicine.